These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33285523)

  • 1. Defining and Managing High-Risk Multiple Myeloma: Current Concepts.
    Costa LJ; Usmani SZ
    J Natl Compr Canc Netw; 2020 Dec; 18(12):1730-1737. PubMed ID: 33285523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knowing the unknowns in high risk multiple myeloma.
    Derman BA; Kosuri S; Jakubowiak A
    Blood Rev; 2022 Jan; 51():100887. PubMed ID: 34479756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to Treat High-Risk Myeloma at Diagnosis and Relapse.
    Caro J; Al Hadidi S; Usmani S; Yee AJ; Raje N; Davies FE
    Am Soc Clin Oncol Educ Book; 2021 Mar; 41():291-309. PubMed ID: 34010042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to Overcome High-Risk Multiple Myeloma.
    Sanchez L
    Cancer J; 2021 May-Jun 01; 27(3):201-204. PubMed ID: 34549908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-risk multiple myeloma: how to treat at diagnosis and relapse?
    Mateos MV; Martínez BP; González-Calle V
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):30-36. PubMed ID: 34889431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chinese expert consensus on diagnosis and treatment of high risk multiple myeloma (2024)].
    ;
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):430-435. PubMed ID: 38964916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies.
    Rees MJ; D'Agostino M; Leypoldt LB; Kumar S; Weisel KC; Gay F
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433520. PubMed ID: 38772002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
    Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
    Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma.
    Marneni N; Chakraborty R
    Curr Hematol Malig Rep; 2021 Apr; 16(2):148-161. PubMed ID: 33876390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)].
    ; ;
    Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):341-346. PubMed ID: 32370461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
    Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
    Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of [
    Stolzenburg A; Lückerath K; Samnick S; Speer M; Kneer K; Schmid JS; Grigoleit GU; Hofmann S; Beer AJ; Bunjes D; Knop S; Buck AK; Einsele H; Lapa C
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1694-1704. PubMed ID: 29610955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
    Kumar AK; Dakhil C; Teeka Satyan M; Haideri N
    J Med Case Rep; 2014 Sep; 8():299. PubMed ID: 25200389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy for relapsed multiple myeloma.
    Aljama MA; Sidiqi MH; Dingli D
    Panminerva Med; 2018 Dec; 60(4):174-184. PubMed ID: 30303355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
    Wahab A; Rafae A; Faisal MS; Mushtaq K; Ehsan H; Khakwani M; Ashraf A; Rehan T; Ahmed Z; Shah Z; Khan A; Anwer F
    Expert Rev Hematol; 2020 Dec; 13(12):1333-1347. PubMed ID: 33078986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
    Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
    Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.